Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ImmuPharma plc
DescriptionSelective phospholipase A2 (PLA2) subtype inhibitor
Molecular Target Phospholipase A2 (PLA2)
Mechanism of ActionPhospholipase A2 inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentDiscovery
Standard IndicationInflammatory disease
Indication DetailsInflammatory disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today